

University of Wollongong - Research Online

Thesis Collection

Title: The development of radiolabelled peripheral benzodiazepine receptor ligands for imaging cancer and neurodegenerative disorders

Author: Taryn P Homes

Year: 2007

Repository DOI:

Copyright Warning

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.

Research Online is the open access repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au

2007

The development of radiolabelled peripheral benzodiazepine receptor ligands for imaging cancer and neurodegenerative disorders

Taryn P. Homes
University of Wollongong

Follow this and additional works at: <https://ro.uow.edu.au/theses>

University of Wollongong

Copyright Warning

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.

Recommended Citation

Homes, Taryn P, The development of radiolabelled peripheral benzodiazepine receptor ligands for imaging cancer and neurodegenerative disorders, PhD thesis, Department of Chemistry, University of Wollongong, 2007. <http://ro.uow.edu.au/theses/65>

NOTE

This online version of the thesis may have different page formatting and pagination from the paper copy held in the University of Wollongong Library.

UNIVERSITY OF WOLLONGONG

COPYRIGHT WARNING

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

The Development of Radiolabelled Peripheral Benzodiazepine
Receptor Ligands for Imaging Cancer and Neurodegenerative
Disorders

Taryn P Homes

B. Med. Chem. Hons.

A thesis submitted in fulfilment of the requirements
for the award of the degree

Doctor of Philosophy

from

University of Wollongong



Department of Chemistry

December 2007

Certification

I, Taryn P. Homes, declare that this thesis, submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the Department of Chemistry, University of Wollongong, is wholly my own work unless otherwise referenced or acknowledged. The document has not been submitted for qualifications at any other academic institute.

Taryn P. Homes

December 2007

Acknowledgements

I would like to express my deepest thanks to the following people...

My supervisors **Dr Andrew Katsifis** (ANSTO) and **Assoc. Prof. Paul Keller** (UOW) for their time and guidance, and for giving me the opportunity to complete a PhD

AINSE for the partial funding of the project and conference funds

Filomena Mattner for teaching me all the pharmacological methods used in this project

Tien Pham for teaching me how to radiolabel

Xiang Liu and **Thomas Bourdier** for their help with metabolite studies

Tim Jackson and **John Howse** for their QC work

The radiopharmaceuticals group at ANSTO, including the **pharmacology group** for helping with animal studies

The Keller Group for their help and support with presentations

The UOW Department of Chemistry technical staff for running mass specs

Office buddies **Mark Ashford**, **Mitchell Quinlivan**, and **Pam Sumner** for making my PhD a lot of fun, and for their help with writing my thesis

Mum, Dad, Steve, Jared, my best friend **Cathy**, and **Vinh**, for being so proud of me

My fiancé **Brad Angel** for his love and support

List of Abbreviations

^{13}C NMR	Carbon Nuclear Magnetic Resonance
^1H NMR	Proton Nuclear Magnetic Resonance
ACN	Acetonitrile
AcOH	Acetic Acid
AIBN	Azobisisobutyronitrile
ANT	Adenine Nucleotide Translocase
Ar	Aryl
bs	Broad singlet
CAT	Chloramine-T
CBR	Central Benzodiazepine Receptor
CI	Chemical Ionisation
CNS	Central Nervous System
DBI	Diazepam Binding Inhibitor
DCM	Dichloromethane
dd	Doublet of doublets
ddd	Doublet of doublets of doublets
DEPT	Distortionless Enhancement by Polarisation Transfer
DMF	Dimethylformamide
DMSO	Dimethylsulfoxide
dt	Doublet of triplets
EAE	Experimental Autoimmune Encephalomyelitis
EI	Electron Impact

ES	Electrospray
FDG	Fluorodeoxyglucose
GABA	Gamma-aminobutyric Acid
GIT	Gastrointestinal Tract
h	Hour
HPLC	High Performance Liquid Chromatography
HRMS	High Resolution Mass Spectrometry
Hz	Hertz
IC ₅₀	Inhibition Constant at 50%
ID/g	Injected dose per gram
IMM	Inner mitochondrial membrane
LE	Lupus Erythmatosus
M	Molar
m	Multiplet
MBq	Megabequerel
min	Minute
mL	Millilitre
mmol	Milli mol
mp.	Melting Point
MS	Mass Spectrometry
<i>m/z</i>	Mass/charge ratio
NBS	<i>N</i> -Bromosuccinimide
OMM	Outer mitochondrial membrane
PBR	Peripheral Benzodiazepine Receptor
PE	Petroleum Ether

PET	Positron Emission Tomography
PPA	Polyphosphoric Acid
q	Quartet
qC	Quaternary Carbon
RCY	Radiochemical Yield
RT	Room Temperature
s	Singlet
SAR	Structure-Activity Relationship
SPECT	Single Photon Emission Computed Tomography
StAR	Steroidogenic acute regulatory protein
t	Triplet
TFA	Trifluoroacetic Acid
THF	Tetrahydrofuran
TLC	Thin Layer Chromatography
Tris	Tris(Hydroxymethyl)aminomethane
UV	Ultraviolet
VDAC	Voltage Dependent Anion Channel

Publications/Presentations

Publications

- **Homes, T.P.**, Keller, P.A., Katsifis, A., Mattner, F. (2006); Synthesis and in vitro binding of *N,N*-dialkyl-2-phenylindol-3-ylglyoxylamides for the peripheral benzodiazepine binding sites; *Bioorganic and Medicinal Chemistry*; 14; 3938-3946
- **Homes, T.P.**, Mattner, F., Keller, P.A., Katsifis, A. (2007); Synthesis and in vivo evaluation of a novel [^{123}I] indolglyoxylamide for the Peripheral Benzodiazepine Binding Sites; *Journal of Labelled Compounds and Radiopharmaceuticals*; 50; S307
- **Homes, T.P.**, Mattner, F., Keller, P.A., Katsifis, A. In vivo evaluation of ^{123}I - *N,N*-diethyl-[5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylamide for the peripheral benzodiazepine binding sites. To be submitted to *Nuclear Medicine and Biology*.

Oral Presentations

- **Homes, T.P.**, Keller, P.A., Katsifis, A. Synthesis and peripheral and central benzodiazepine receptor binding affinity of *N,N*-dialkyl-2-phenylindol-3-ylglyoxylamides. RACI Young Chemist's Symposium, 3rd July 2005, University of Sydney
- **Homes, T.P.**, Keller, P.A., Katsifis, A., Mattner, F. Development of radiolabelled peripheral benzodiazepine receptor ligands. University of Wollongong Department of Chemistry Annual Conference. 24-25th October, 2005, ANU Kialoa coastal campus.

Poster Presentations

- **Homes, T.P.**, Keller, P.A., Katsifis, A., Mattner, F. (2006); Synthesis and evaluation of *N,N*-dialkyl-2-phenylindol-3-ylglyoxylamides for the study of peripheral benzodiazepine binding sites; 4th France – Australia Symposium on Nuclear Medicine, Melbourne
- **Homes, T.P.**, Mattner, F., Keller, P.A., Katsifis, A. (2007); Synthesis and in vivo evaluation of a novel [¹²³I] indolglyoxylamide for the peripheral benzodiazepine binding sites; 17th International Symposium on Radiopharmaceutical Science, 29th April-3rd May, Aachen, Germany

Abstract

Three classes of compounds were chosen for investigation to find a high affinity and selective iodinated peripheral benzodiazepine receptor (PBR) ligand; indol-3-ylglyoxylamides, pyrazolopyrimidines, and pyridopyrrolooxazepines and pyrrolobenzoxazepines. These compounds were chosen from a literature search for their high PBR affinity and selectivity, ease of synthesis, and the potential for radioiodination.

Fifteen new halogenated *N,N*-dialkylindol-3-ylglyoxylamides were synthesised and tested for their PBR and central benzodiazepine receptor (CBR) affinity. The compounds IC₅₀ values for the PBR ranged from 7.8 – 618 nM, and a structure activity relationship (SAR) was determined. Brominated compounds had higher binding affinities than their iodinated analogues, and indoles with a chloro substituent on position 5 had higher binding affinities than the non-chlorinated compounds. The optimum alkyl chain length was found to be two carbons. The highest affinity iodinated ligand, with a PBR IC₅₀ of 8.2 nM, was radiolabelled with ¹²³I in 55-60% radiochemical yield and evaluated *in vivo* in Sprague-Dawley rats. Biodistribution studies revealed high uptake of the radiotracer in organs known to contain PBR, such as the kidneys, adrenals, heart, liver and lungs. Drug competition studies showed that the PBR drugs PK11195 and Ro5-4864, when injected into the rat 5 min prior to injection of the radiotracer, significantly decreased uptake of radiotracer into those organs. The CBR drug, flumazenil, did not decrease the uptake of the radiotracer. Metabolite studies showed that the radiotracer was > 95% intact in the heart, kidneys, adrenals, and brain after 3 h and was 65% intact in the plasma. This compound is the first radiolabelled

PBR ligand of this class, and is an excellent candidate for future studies and may lead to a clinically useful imaging agent.

Three pyrazolopyrimidines were synthesised, with lengths of the alkyl chains being methyl, ethyl, or propyl groups. The highest affinity ligand, with the propyl groups, displayed an IC_{50} of 7.9 nM, however, only the compound with ethyl groups displaying an IC_{50} of 11.7 nM was radiolabelled with ^{123}I in 95% radiochemical yield, and evaluated *in vivo* in rats. This compound showed high uptake into organs known to contain PBR, and also showed an interesting result in which pre-administration of Ro5-4864 did not cause any significant decrease of uptake of radiotracer in the kidney or heart, however PK11195 did cause of significant decrease in these organs. This compound provides the first radioiodinated PBR ligand of this class.

Two pyrrolopyridooxazepines and two pyrrolobenzoxazepines were synthesised and tested. One of the compounds was found to be inactive, while the others had moderate PBR IC_{50} values of 24-39 nM. The moderate binding affinity for these compounds would unlikely lead to a successful imaging agent.

Table of Contents

Certification	ii
Acknowledgements	iii
List of Abbreviations	iv
Publications/Presentations	vii
Abstract	ix
Table of Contents	xi
List of Figures	xvii
List of Schemes	xxi
List of Tables	xxiii
1 Introduction	1
1.1 Peripheral Benzodiazepine Receptors	1
1.2 Molecular Structure of the PBR	2
1.3 Cellular and Tissue Location of the PBR	4
1.4 Endogenous Ligands for the PBR	5
1.5 Synthetic PBR Ligands	7
1.6 Possible Functions of the PBR	9
1.6.1 Cellular Respiration	9
1.6.2 Steroid and Bile Acid Biosynthesis	9
1.6.3 Modulation of Apoptosis	12
1.6.4 Cellular Proliferation and Differentiation	12
1.6.5 Immune Responses	13
1.7 The PBR under Pathological Conditions	14
1.7.1 Neurodegenerative Disorders	14

1.7.2	Inflammation and Autoimmune Diseases	15
1.7.3	Cancer	16
1.8	Peripheral Benzodiazepine Receptor Ligands	17
1.8.1	Benzodiazepines	17
1.8.2	Isoquinoline Carboxamides	18
1.8.3	Imidazopyridines and Imidazopyridazines	18
1.8.4	Pyrazolopyrimidines	20
1.8.5	Pyrrolobenzothiazepines, pyrrolobenzoxazepines and pyridopyrrolooxazepines	21
1.9	Radiopharmaceutical Chemistry	26
1.9.1	Radionuclides	26
1.9.2	Radiopharmaceuticals	27
1.9.3	Radiation Detection	28
1.10	Radiolabelled PBR Ligands	31
1.10.1	Iodine-123 Radiolabelled PBR Ligands	33
1.11	Project Aims	34
2	Synthesis of <i>N,N</i> -Dialkyl-2-phenylindol-3-yl-glyoxylamides	36
2.1	<i>N,N</i> -Dialkyl-2-phenylindol-3-ylglyoxylamides for the PBR	36
2.2	Target Compounds	37
2.3	General Synthetic Strategy	39
2.4	Synthesis of 5-Chloroindol-3-ylglyoxylamide Analogues	40
2.4.1	Synthesis of Glyoxylyl Chloride Intermediates	40
2.4.2	Synthesis of <i>N,N</i> -Dialkyl-[5-chloro-2-(4-halophenyl)-indol-3-yl]- glyoxylamides	41
2.5	Synthesis of Indol-3-ylglyoxylamide Analogues	45

2.5.1	Synthesis of Glyoxylyl Chloride Intermediates	45
2.5.2	Amination of [2-(4-Halophenyl)indol-3-yl]glyoxylyl Chlorides	48
2.6	Synthesis of <i>meta</i> -Substituted Indol-3-ylglyoxylamide Analogues	49
2.7	Synthesis of 2-(4-Fluorophenyl)indol-3-ylglyoxylamide Analogue	52
2.8	<i>In Vitro</i> Binding of <i>N,N</i> -Dialkyl-2-phenylindol-3-ylglyoxylamides	54
2.9	Lipophilicity Estimations	57
2.10	Comparison with Similar New Indolylglyoxylamides	58
2.11	Conclusion	60
3	Synthesis of 2-Arylpyrazolo[1,5- <i>a</i>]-pyrimidin-3-yl Acetamides	61
3.1	2-Arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl Acetamides	61
3.2	Rationale	64
3.3	General Synthetic Strategy	64
3.4	Synthesis of 4-Iodobenzoylacetonitrile Intermediate	66
3.5	Synthesis of Iodinated <i>N,N</i> -Dialkylbutanamides	67
3.6	Synthesis of 3-Aminopyrazoles	70
3.7	Synthesis of Pyrazolopyrimidines	71
3.8	<i>In Vitro</i> Binding of 2-Arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl Acetamides	73
3.9	Conclusions and Future Directions	74
4	Synthesis of Pyridopyrrolooxazepines and Pyrrolobenzoxazepines	77
4.1	Pyrrolobenzothiazepines for the PBR	77
4.2	Pyridopyrrolo and Pyrrolobenzoxazepine Ligands for PBR	77
4.3	Rationale	79
4.4	General Synthetic Scheme	79
4.5	Synthesis of Ethyl (\pm)- α -Bromoarylacetates	81
4.6	Synthesis of Pyridopyrrolooxazepines	81

4.7	Synthesis of Pyrrolobenzoxazepines	87
4.8	Synthesis of 4-Halogenated Pyrrolobenzoxazepines	90
4.9	<i>In Vitro</i> Binding of Pyridopyrrolooxazepines and Pyrrolobenzoxazepines	92
4.10	Conclusions and Future Directions	94
5	Radioiodination and <i>In Vivo</i> Studies	95
5.1	Radioiodination Methods	95
5.2	Synthesis of ^{123}I Compounds	97
5.2.1	Synthesis of [^{123}I]N,N-Diethyl-(5-chloro-2-(4-iodophenyl)indol-3-yl)glyoxylamide	97
5.2.2	Synthesis of [^{123}I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl]acetamide	101
5.3	<i>In Vivo</i> Biodistribution Studies	104
5.3.1	<i>In Vivo</i> Biodistribution of [^{123}I]N,N-Diethyl-(5-chloro-2-(4-iodophenyl)indol-3-yl)glyoxylamide [142]	104
5.3.2	<i>In Vivo</i> Biodistribution of [^{123}I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl]acetamide [144]	107
5.4	<i>In Vivo</i> Competition Studies	109
5.4.1	<i>In Vivo</i> Competition Study of [^{123}I]N,N-Diethyl-(5-chloro-2-(4-iodophenyl)indol-3-yl)glyoxylamide [142]	109
5.4.2	Competition Study of [^{123}I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl]acetamide [144]	112
5.5	<i>In Vivo</i> Stability Studies	114
5.5.1	<i>In Vivo</i> Stability Study of [^{123}I]N,N-Diethyl-(5-chloro-2-(4-iodophenyl)indol-3-yl)glyoxylamide [142]	114

5.5.2	<i>In Vivo</i> Stability Study of [¹²³ I] <i>N,N</i> -Diethyl-[2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl]acetamide [144]	115
5.6	Conclusion and Future Directions	117
6	Conclusions and Future Directions	118
7	Experimental	121
7.1	General Experimental	121
7.2	Experimental Procedures for the Synthesis of Indole Compounds	123
7.2.1	Experimental Procedures for the Synthesis of 5-Chlorosubstituted Indol-3-ylglyoxylamides	123
7.2.2	Experimental Procedures for the Synthesis of Indol-3-ylglyoxylamides	133
7.2.3	Experimental Procedures for the Synthesis of <i>meta</i> -Substituted Phenylindol-3-ylglyoxylamides	141
7.2.4	Experimental Procedures for the Synthesis of Fluorinated Indol-3-ylglyoxylamides	146
7.3	Experimental Procedures for the Synthesis of 2-Arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl Acetamides	148
7.4	Experimental Procedure for the Synthesis of Pyrrolobenzoxazepine and pyridopyrrolooxazepine compounds	159
7.4.1	Synthesis of Ethyl (±)- α -bromophenylacetates	159
7.4.2	Experimental Procedures for the Synthesis of Pyridopyrrolo-oxazepines	162
7.4.3	Experimental Procedures for the Synthesis of Pyrrolobenzoxazepines	170

7.5	Experimental Procedures for the Stannylation Reactions and Radioiodination Reactions	179
7.6	Pharmacology Methods	182
7.6.1	<i>In Vitro</i> Binding Assays for Peripheral Benzodiazepine Receptors	182
7.6.2	<i>In Vitro</i> Binding Assays for Central Benzodiazepine Receptors	183
7.6.3	<i>In Vivo</i> Biodistribution Studies for [^{123}I]PBR200 [142] and [^{123}I]PBR215 [144]	185
7.6.4	<i>In Vivo</i> Competition Studies for [^{123}I]PBR200 [142] and [^{123}I]PBR215 [144]	186
7.6.5	<i>In Vivo</i> Stability Studies for [^{123}I]PBR200 [142] and [^{123}I]PBR215 [144]	187
7.7	Lipophilicity Estimations	188
8	References	189

List of Figures

Figure 1.1	A schematic diagram of the structure of the PBR complex in the mitochondria.	3
Figure 1.2	Possible endogenous PBR ligands.	6
Figure 1.3	Synthetic PBR ligands.	8
Figure 1.4	The mechanism of steroid and bile acid biosynthesis in the mitochondria of steroid producing cells and hepatic cells respectively.	10
Figure 1.5	Hypothetical model for cholesterol transport into mitochondria.	12
Figure 1.6	Structure of Ro5-4864 [6] and diazepam [11].	17
Figure 1.7	Imidazo[1,2- <i>a</i>]pyridine-3-acetamides [12], alpidem [7] and zolpidem [13].	19
Figure 1.8	General structure of imidazo[1,2- <i>a</i>]pyridine-3-acetamides [14]-[16].	20
Figure 1.9	General structure of 2-arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl acetamides [17].	20
Figure 1.10	Potent PBR ligands: pyrrolobenzothiazepines [18], pyrrolobenzoxazepines [19], and pyridopyrrolooxazepines [20].	21
Figure 1.11	Opening of the diazepine ring of Ro5-4864 leading to new PBR ligands based on aryloxyanilide derivatives [21].	22
Figure 1.12	Structures of DAA1106 [22] and DAA1097 [23].	23
Figure 1.13	The basic structure of 2-aryl-3-indoleacetamides (FGIN-1) [24], and FGIN-1-44 [25].	24

Figure 1.14	General structure of 3-aryl-3-pyrrol-1-ylpropanamides, analogues of FGIN-1 [24].	24
Figure 1.15	Structure of <i>N,N</i> -dialkyl-2-phenylindol-3-ylglyoxyamides [27].	25
Figure 1.16	PET detector and brain images obtained with a SPECT camera.	29
Figure 1.17	DAA1106 radiolabelled with ^{18}F .	31
Figure 1.18	^{11}C PK11195 [31] and PK11195 derivative, ^{11}C VC195 [30].	31
Figure 1.19	Carbon-11 radiolabelled pyrazolopyrimidine, ^{11}C DPA-713 [32].	32
Figure 1.20	^{123}I radiolabelled PBR ligands.	33
Figure 1.21	Proposed compound classes for synthesis and investigation.	35
Figure 2.1	Structure of <i>N,N</i> -dialkyl-2-phenylindol-3-ylglyoxylamides.	36
Figure 2.2	Structures and PBR binding affinities for several <i>N,N</i> -dialkyl-2-phenylindol-3-ylglyoxylamides.	37
Figure 2.3	Possible variations for the target indol-3-ylglyoxylamides.	38
Figure 2.4	Iodinated target compound with the iodine on the alkyl chain.	38
Figure 2.5	^1H and ^{13}C NMR spectra similarities in the indole moiety for indol-3-ylglyoxylamides [48]-[54].	45
Figure 2.6	^1H and ^{13}C NMR spectra similarities in the indole moiety for indol-3-ylglyoxylamides [63]-[67].	49
Figure 2.7	A fitted sigmoid curve showing the PBR IC_{50} of [65].	54
Figure 3.1	Basic structure of alpidem [7] and 2-arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl acetamide derivatives [17].	61
Figure 3.2	Structure of 2-phenylpyrazolo[1,5- <i>a</i>]pyrimidinyl-3-yl acetamides.	62
Figure 3.3	Target iodinated 2-arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl acetamides.	66
Figure 3.4	^1H NMR spectra assignments of butanamide [95], typical of butanamides [96]-[98].	69

Figure 3.5	¹ H NMR assignment of [91], typical of target compounds [90]-[92].	72
Figure 3.6	PBR and CBR binding affinities of [90]-[92].	74
Figure 4.1	General structure of pyrrolobenzothiazepines for the PBR.	77
Figure 4.2	Selected pyridopyrrolooxazepines and pyrrolobenzoxazepines and their binding affinities (<i>K_i</i>) for PBR.	78
Figure 4.3	Compound showing possible positions for radiolabelling with ¹²³ I.	79
Figure 4.4	Proposed mechanism of radical reaction to form pyrido[3,2- <i>b</i>]pyrrolo[1,2- <i>d</i>][1,4]oxazine-6-one [122].	85
Figure 4.5	PBR and CBR IC ₅₀ values for compounds [121], [123], [128], [130].	93
Figure 5.1	Radioiodination via nucleophilic addition to synthesise radioiodinated PK11195.	95
Figure 5.2	Direct radioiodination (radioiodo-deprotonation) of tyrosine.	96
Figure 5.3	Electrophilic radioiodination of a tributylstannyl group.	96
Figure 5.4	Structure of two oxidants, chloramine-T and iodogen.	97
Figure 5.5	Purification of [¹²³ I]PBR200 using a semipreparative RP HPLC column.	99
Figure 5.6	Coinjection of iodo standard [50] with [¹²³ I]PBR200 [142] onto HPLC.	100
Figure 5.7	HPLC purification of [¹²³ I]PBR200 when using chloramine-T.	100
Figure 5.8	HPLC purification [¹²³ I]PBR215 when used chloramine-T.	103
Figure 5.9	Purification of [¹²³ I]PBR215 (at 12 min) using a semipreparative RP HPLC column.	104
Figure 5.10	Biodistribution of [¹²³ I]PBR200 in male Sprague-Dawley rats.	105
Figure 5.11	Biodistribution of [¹²³ I]PBR200 in Sprague-Dawley rats in blood, brain, olfactory bulbs and testes.	106

Figure 5.12 Biodistribution of [^{123}I]PBR215 in male Sprague-Dawley rats.	108
Figure 5.13 Biodistribution of [^{123}I]PBR215 in blood, brain, olfactory bulbs and testes.	109
Figure 5.14 Effects of various drugs on [^{123}I]PBR200 uptake in rat organs.	110
Figure 5.15 Effects of various drugs on [^{123}I]PBR200 uptake in rat blood, brain and olfactory bulbs.	111
Figure 5.16 Effects of various drugs on [^{123}I]PBR215 uptake in rat organs.	113
Figure 5.17 Effects of various drugs on [^{123}I]PBR215 uptake in rat organs.	113
Figure 5.18 <i>In vivo</i> stability study of [^{123}I]PBR215 in Sprague-Dawley rats.	116

List of Schemes

Scheme 2.1 General synthesis of <i>N,N</i> -dialkyl-2-phenylindol-3-ylglyoxylamides.	39
Scheme 2.2 Synthesis of [5-chloro-2-(4-halophenyl)indol-3-yl]glyoxylyl chlorides [46] and [47].	41
Scheme 2.3 Amination of [5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylyl chloride [46].	42
Scheme 2.4 Amination of [5-chloro-2-(4-bromophenyl)indol-3-yl]glyoxylyl chloride [47].	44
Scheme 2.5 Synthesis of non-chlorinated glyoxylyl chlorides.	46
Scheme 2.6 Synthesis of 2-(4-bromophenyl)indole [60] via the Fischer indole synthesis.	47
Scheme 2.7 Amination of [2-(4-halophenyl)indol-3-yl]glyoxylyl chlorides [61]-[62].	48
Scheme 2.8 Synthesis of <i>N,N</i> -diethyl-[5-chloro-2-(3-iodophenyl)indol-3-yl]glyoxylamide [73].	50
Scheme 2.9 Proposed synthetic scheme for the synthesis of <i>N</i> -((<i>E</i>)-3-iodoallyl)- <i>N</i> -methyl-2-(4-fluorophenyl)indol-3-ylglyoxylamide [41].	53
Scheme 3.1 General synthetic scheme for synthesis of 2-arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-ylacetamides.	65
Scheme 3.2 Synthesis of key intermediate 4-iodobenzoylacetone nitrile [89].	67
Scheme 3.3 Synthesis of butanamides [95]-[98].	68
Scheme 3.4 Mechanism for the synthesis of dialkylated product [99].	70
Scheme 3.5 Reaction of [96] with hydrazine hydrate in ethanol.	71

Scheme 3.6 Synthesis of pyrazoles [100]-[102].	71
Scheme 3.7 Synthesis of 2-arylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl acetamides [90]-[92].	72
Scheme 4.1 General synthetic scheme for pyrrolobenzoxazepines and pyridopyrrolooxazepines.	80
Scheme 4.2 Synthesis of ethyl (\pm)- α -bromophenylacetates [112] and [113].	81
Scheme 4.3 General synthesis of 7-[(diethylcarbamoyl)oxy]-6-(4-iodophenyl)pyrido-[3,2- <i>b</i>]pyrrolo[1,2- <i>d</i>][1,4]oxazepine [121].	83
Scheme 4.4 An unexpected side-product from an O-alkylation reaction.	84
Scheme 4.5 Carbon alkylation of [120] when using DMF as solvent.	86
Scheme 4.6 Complete synthesis of target pyrrolobenzoxazepines [128] and [130].	88
Scheme 4.7 Carbon alkylation of [127] using DMF as solvent.	90
Scheme 4.8 Attempted synthesis of 7-[(diethylcarbamoyl)oxy]-4-iodo-6-phenylpyrrolo[2,1- <i>d</i>][1,5]benzoxazepine [138].	91
Scheme 5.1 Synthesis of [123 I] <i>N,N</i> -diethyl-(5-chloro-2-(4-iodophenyl)indol-3-yl)glyoxylamide [142].	98
Scheme 5.2 Synthesis of [123 I] <i>N,N</i> -diethyl-[2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5- <i>a</i>]pyrimidin-3-yl]acetamide [144].	102

List of Tables

Table 1.1 Difference between PBR and CBR.	2
Table 1.2 Radionuclides and their uses.	28
Table 2.1 Reaction and purification conditions and yields for compounds [48]-[51].	42
Table 2.2 ¹ H and ¹³ C NMR alkyl chain peak assignments for compounds [48]-[51].	43
Table 2.3 Reaction and purification conditions and yields for compounds [52]-[54].	44
Table 2.4 Reaction and purification conditions and yields for compounds [63]-[67].	48
Table 2.5 PBR and CBR binding affinities (IC ₅₀) of halogenated indolglyoxylamides.	55
Table 2.6 PBR K _i values of similar new indolylglyoxylamides.	59
Table 3.1 PBR binding affinities of selected 2-arylpyrazolo[1,5- <i>a</i>]pyrimidinyl-3-yl acetamides.	63